Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Revenue (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Revenue over the past 3 years, most recently at $5.4 million for Q4 2025.

  • Quarterly results put Revenue at $5.4 million for Q4 2025, up 108.75% from a year ago — trailing twelve months through Dec 2025 was $13.1 million (up 29.85% YoY), and the annual figure for FY2025 was $13.1 million, up 29.85%.
  • Revenue for Q4 2025 was $5.4 million at Tonix Pharmaceuticals Holding, up from $3.3 million in the prior quarter.
  • Over the last five years, Revenue for TNXP hit a ceiling of $5.4 million in Q4 2025 and a floor of $2.0 million in Q2 2025.
  • Median Revenue over the past 3 years was $2.8 million (2024), compared with a mean of $3.1 million.
  • Biggest five-year swings in Revenue: plummeted 37.7% in 2024 and later soared 108.75% in 2025.
  • Tonix Pharmaceuticals Holding's Revenue stood at $3.8 million in 2023, then crashed by 31.68% to $2.6 million in 2024, then skyrocketed by 108.75% to $5.4 million in 2025.
  • The last three reported values for Revenue were $5.4 million (Q4 2025), $3.3 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.